Several studies suggest that stress-related catecholamine release accelerates cancer progression, so the targeting of β-adrenergic receptors (β-ARs) has been proposed as a potential therapeutic approach to cancer and, in particular, melanoma [13, 14]. This evidence concerns the gene CTBP1 and cancer.